RD3 regulator of GUCY2DGenealiases: C1orf36 · LCA12
Q-omics provides the consensus-scored RD3 profile across patient tissues and cancer cell-line models. RD3 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, RD3 is differentially expressed in 11, with the highest sampling consensus in LUAD. Additionally, RD3 RNA expression shows 13,666 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRP, LUAD, and TGCT as cancer lineages where RD3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RD3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RD3 survival associations across molecular data types. RD3 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RD3 RNA expression–survival associations across cancer types. High RD3 expression shows unfavorable associations in KIRP and UVM, but favorable associations in OV, LUAD, KIRC and LGG. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for RD3 RNA expression.
This table summarizes RD3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for RD3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RD3 shows lower tumor expression in LUAD, LUSC and KICH and higher tumor expression in BRCA, HNSC and UCEC. The LUAD box plot shows higher RD3 RNA expression in normal versus tumor tissue (log2 FC = −0.213, t-test p < 0.001).
This table shows molecular features associated with RD3 in patient tissues and cancer cell lines. In patient samples, RD3 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, RD3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and SOFT_TISSUE.
